Study of ORIC-944 in Patients With Metastatic Prostate Cancer (NCT05413421)
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Rocky Mountain Cancer Center — Colorado Springs, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Rocky Mountain Cancer Center — Colorado Springs, Colorado
- South Florida Oncology and Hematology — Plantation, Florida
- Illinois Cancer Specialists — Arlington Heights, Illinois
- Comprehensive Urologic Care — Lake Barrington, Illinois
- First Urology — Jeffersonville, Indiana
- Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland — Baltimore, Maryland
- Maryland Oncology Hematology — Silver Spring, Maryland
- Karmanos — Detroit, Michigan
- Minnesota Oncology Hematology — Minneapolis, Minnesota
- Memorial Sloane Kettering Cancer Center — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Keystone Urology Specialists — Lancaster, Pennsylvania
- Amarillo Urology Research — Amarillo, Texas
- Urology Clinics of North Texas — Dallas, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- Virginia Oncology Associates — Fairfax, Virginia
- Virginia Cancer Specialists — Norfolk, Virginia
- University of Washington, Fred Hutchinson Cancer Center — Seattle, Washington
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
- Sydney Adventist Health — Wahroonga, New South Wales
- Bendigo Health — Bendigo, Victoria
- Peninsula Health — Frankston, Victoria
- NEXT Oncology — Barcelona, Barcelona
- Vall d'Hebron Institute of Oncology — Barcelona, Barcelona
📞 Contact the Study Coordinator
Phone: (650) 388-5600
Email: clinical@oricpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.